Bio-Techne (Bio-Techne) Scaled Net Operating Assets : 0.87 (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Bio-Techne Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Bio-Techne's operating assets for the quarter that ended in Dec. 2023 was $2,595 Mil. Bio-Techne's operating liabilities for the quarter that ended in Dec. 2023 was $211 Mil. Bio-Techne's Total Assets for the quarter that ended in Sep. 2023 was $2,755 Mil. Therefore, Bio-Techne's scaled net operating assets (SNOA) for the quarter that ended in Dec. 2023 was 0.87.

Bio-Techne Scaled Net Operating Assets Historical Data

The historical data trend for Bio-Techne's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Techne Scaled Net Operating Assets Chart

Bio-Techne Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Scaled Net Operating Assets

Get a 7-Day Free Trial

0.94

0.82

0.87

0.79

0.97

Bio-Techne Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Scaled Net Operating Assets	Get a 7-Day Free Trial															0.82	0.93	0.85	0.91	0.87

Competitive Comparison of Bio-Techne's Scaled Net Operating Assets

For the Biotechnology subindustry, Bio-Techne's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Techne's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bio-Techne's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Bio-Techne's Scaled Net Operating Assets falls into.

Bio-Techne Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Bio-Techne's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Jun. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Jun. 2023 )
=	(Operating Assets (A: Jun. 2023 )	-	Operating Liabilities (A: Jun. 2023 ))	/	Total Assets (A: Jun. 2022 )
=	(2434.382	-	217.211)	/	2294.805
=	0.97

where

	Operating Assets		(A: Jun. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	2638.692	-	204.31
=	2434.382

	Operating Liabilities		(A: Jun. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	672.176	-	443.766	-	11.199
=	217.211

Bio-Techne's Scaled Net Operating Assets (SNOA) for the quarter that ended in Dec. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Dec. 2023 )
=	(Operating Assets (Q: Dec. 2023 )	-	Operating Liabilities (Q: Dec. 2023 ))	/	Total Assets (Q: Sep. 2023 )
=	(2595.101	-	211.495)	/	2755.36
=	0.87

where

	Operating Assets		(Q: Dec. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	2730.753	-	135.652
=	2595.101

	Operating Liabilities		(Q: Dec. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	767.194	-	543.027	-	12.672
=	211.495

Bio-Techne Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Bio-Techne's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Techne (Bio-Techne) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bio-Techne Corp (NAS:TECH) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

TE1:Germany T1CH34:Brazil

Address

614 McKinley Place N.E., Minneapolis, MN, USA, 55413

Website

https://www.bio-techne.com

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Executives

Roeland Nusse	director	473 TENNESSEE, PALO ALTO CA 94306
William Geist	officer: PRESIDENT, PROTEIN SCIENCES	900 MIDDLESEX TURNPIKE, C/O QUANTERIX CORPORATION, BILLERICA MA 01821
Charles R. Kummeth	director, officer: Chief Executive Officer	425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
Shane Bohnen	officer: SVP - General Counsel	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Brenda S. Furlow	officer: SVP - General Counsel	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
John L Higgins	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Robert V Baumgartner	director	5775 WAYZATA BOULEVARD, SUITE 400, MINNEAPOLIS MN 55416
Kim Kelderman	officer: Pres. Diagnostics & Genom	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Norman David Eansor	officer: SVP Biotech	8100 SOUTHPARK WAY, A-8, LITTLETON CO 80120
James Hippel	officer: Chief Financial Officer	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Joseph D Keegan	director	C/O MOLECULAR DEVICES CORP, 1311 ORLEANS DRIVE, SUNNYVALE CA 94089
Alpna Seth	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413
Julie L Bushman	director	185 SOUTH 84TH STREET, SUITE 200, MILWAUKEE WI 53214
Rupert Vessey	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Randolph C Steer	director	614 MCKINLEY PLACE NE, MINNEAPOLIS MN 55413